BioArctic Neuroscience AB
– Novel treatments to help patients with CNS disorders
BioArctic Neuroscience develops new treatments for neurodegenerative diseases with huge unmet medical need. The company is working with antibodies and proteins in neurologic disorders. The company was founded 2003 and has 25 employees in Stockholm. The R&D portfolio comprises of several novel therapeutic projects in different stages of development.
Today only symptomatic treatments are available and a treatment slowing down or halting the progression of the disease would be of great benefit for the patients. BioArctic´s most advanced project is BAN2401, a humanized monoclonal antibody selectively targeting the toxic Aß protofibrils, which are central for disease progression and toxicity in Alzheimer’s disease. BAN2401, intended as a disease modifying treatment, is now in late clinical development as the company’s lead immunotherapeutic drug candidate developed with BioArctic’s technology. The antibody was developed in collaboration with Rudbeck Laboratory, Uppsala University. In collaboration with Eisai and Biogene Idec a phase IIb clinical trial is ongoing in early Alzheimer patients in the US, Canada, EU and Japan.
Complete Spinal Cord Injury
No treatment exists for these patients today. A growth factor and a medicinal device will in combination be used during neurosurgical procedures to recreate a functional spinal cord in subjects with a total loss of motor and sensory function in the legs. To promote nerve grafting procedures, a biodegradable device has been constructed where a growth factor is inserted together with peripheral nerves. The product is used during the neurosurgical procedure, when injured tissue is replaced, to connect viable nerves on each side of the injured segment. The project is built on innovative research from Karolinska Institutet, the Karolinska University Hospital and Ångström laboratory in Uppsala. The drug candidate received Orphan Drug Designation in EU 2010 and the US 2011. A clinical study is ongoing in Sweden and will also include Denmark and Finland. The project has received funding from Vinnova and EU Horizon2020.
Image provided by Dr. Björn Hedman, Rehabstation Stockholm showing robotic training used for rehabilitation
Current treatments for Parkinson’s disease are based on increasing the levels of dopamine in the brain. These drugs can’t stop the disease progression and do not affect all symptoms of the disease. Today, there is no drug approved for a related disorder i.e. Dementia with Lewy bodies. BioArctic develops new treatments for these diseases. The target is the toxic soluble aggregates of the protein α-synuclein, which is now believed to be the culprit of these disorders. BioArctic has developed antibodies that can remove or inactivate these toxic forms of α-synuclein with encouraging preclinical results. This treatment has the potential to halt the disease progression.